182 related articles for article (PubMed ID: 17072721)
1. Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.
Tsuneoka N; Kuroki T; Haraguchi M; Furui J
Surg Today; 2006; 36(11):989-93. PubMed ID: 17072721
[TBL] [Abstract][Full Text] [Related]
2. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
5. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
7. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
Mac K; Wójcik M
Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
[TBL] [Abstract][Full Text] [Related]
9. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
Graham J; Debiec-Rychter M; Corless CL; Reid R; Davidson R; White JD
Arch Pathol Lab Med; 2007 Sep; 131(9):1393-6. PubMed ID: 17824795
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
Prakash S; Sarran L; Socci N; DeMatteo RP; Eisenstat J; Greco AM; Maki RG; Wexler LH; LaQuaglia MP; Besmer P; Antonescu CR
J Pediatr Hematol Oncol; 2005 Apr; 27(4):179-87. PubMed ID: 15838387
[TBL] [Abstract][Full Text] [Related]
12. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
13. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
14. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
[No Abstract] [Full Text] [Related]
15. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
16. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
Kong M; Wang YL; Xu LJ; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191
[TBL] [Abstract][Full Text] [Related]
17. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
18. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
Gao J; Dang Y; Sun N; Li J; Shen L
Med Oncol; 2012 Dec; 29(5):3039-45. PubMed ID: 22815156
[TBL] [Abstract][Full Text] [Related]
19. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K
Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
[TBL] [Abstract][Full Text] [Related]
20. Imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]